ExaWizards、乳がん患者向けウェアラブル研究をASCO 2026で発表

ExaWizards and ExaMD have presented the results of a wearable device study focused on breast cancer patients at ASCO 2026, the annual conference of the American Society of Clinical Oncology. The research was conducted as a joint project with Kansai Medical University, Daiichi Sankyo, and other partners. By presenting at ASCO, a major international platform for oncology research and clinical practice, the companies are bringing their wearable technology and findings to a global audience of cancer specialists and medical professionals. The collaboration reflects a strategy to combine AI and healthcare expertise with established pharmaceutical and academic institutions to advance patient care through wearable monitoring technology. While the announcement confirms the presentation and the participating organizations, the detailed clinical findings and specific capabilities of the wearable device are to be revealed through the ASCO 2026 session.

ExaWizards and ExaMD's presentation at ASCO 2026 marks a notable step in bringing Japanese technology companies into the international clinical research sphere. The partnership with Kansai Medical University and Daiichi Sankyo—a major Japanese pharmaceutical corporation—demonstrates a coordinated approach to wearable monitoring for oncology patients. By presenting at ASCO, one of the world's premier gatherings for cancer researchers and clinicians, the team is seeking validation and visibility for its work within the global medical community. The specific focus on breast cancer patients suggests a targeted application where wearable devices could support continuous monitoring, potentially improving treatment outcomes or patient management.

No comments yet. Be the first to share your thoughts!